Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.06.181PMID 15570079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of gefitinib in recurrent glioblastoma.

  2004cited by this paper
• First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.

  2004cited by this paper
• Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma

  2004cited by this paper
• Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

  2004cited by this paper
• Salvage Chemotherapy with CPT-11 for Recurrent Glioblastoma Multiforme

  2004cited by this paper
• Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.

  2003cited by this paper
• Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.

  2003cited by this paper
• Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.

  2002cited by this paper
• Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

  2002cited by this paper
• Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study

  2002cited by this paper
• Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.

  2002cited by this paper
• Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

  2002cited by this paper
• Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.

  2002cited by this paper
• PCV chemotherapy for recurrent glioblastoma multiforme

  2001cited by this paper
• New strategy developments in brain tumor therapy.

  2001cited by this paper
• Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.

  2000cited by this paper
• Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts

  2000cited by this paper
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

  2000cited by this paper
• Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

  1999cited by this paper
• Irinotecan therapy in adults with recurrent or progressive malignant glioma.

  1999cited by this paper
• Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

  1998cited by this paper
• Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

  1997cited by this paper
• Chemotherapy response criteria in malignant glioma

  1997cited by this paper
• Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts

  1996cited by this paper
• Response criteria for phase II studies of supratentorial malignant glioma.

  1990cited by this paper
• DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells

  1980cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology

  2025cites this paper
• Identification of low-toxicity DNA topoisomerase I inhibitors with potential blood–brain barrier penetrability for glioblastoma therapy: structure-based virtual screening reveals promising novel Scaffolds

  2025cites this paper
• Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomas

  2025cites this paper
• Local Delivery of Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of Administration

  2024cites this paper
• Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumor recurrence in a glioblastoma tumor model

  2024cites this paper
• Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

  2022cites this paper
• Laser Interstitial Thermal Therapy for Recurrent Glioblastoma: Pooled Analyses of Available Literature.

  2021cites this paper
• Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle

  2021influential citation
• Modulation of Blood–Brain Barrier Permeability by Activating Adenosine A2 Receptors in Oncological Treatment

  2021cites this paper
• Treatment of recurrent glioblastoma: state-of-the-art and future perspectives

  2020cites this paper
• Chemotherapy for Brain Tumors

  2020cites this paper
• Salvage Radiation Therapy for Patients With Relapsing Glioblastoma Multiforme and the Role of Slow Fractionation

  2020cites this paper
• Injectable SN-38-embedded Polymeric Microparticles Promote Antitumor Efficacy against Malignant Glioma in an Animal Model

  2020influential citation
• Anaplastic Astrocytoma

  2020cites this paper
• PEGylated Solid Lipid Nanoparticles for Brain Delivery of Lipophilic Kiteplatin Pt(IV) Prodrugs: an In Vitro Study.

  2020cites this paper
• Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.

  2020cites this paper
• Novel Relationships of Splicing Factors and Regulation in TMZ-Resistant Glioblastoma

  2019cites this paper
• Developing a novel strategy to treat glioblastoma : improving brain bioavailability of sorafenib with a synthetic flavonoid dimer to inhibit drug efflux in blood brain barrier

  2018cites this paper
• The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis.

  2018cites this paper
• Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine

  2018cites this paper
• Biodegradable hybrid-structured nanofibrous membrane supported chemoprotective gene therapy enhances chemotherapy tolerance and efficacy in malignant glioma rats

  2018cites this paper
• Overview on current treatment standards in high-grade gliomas.

  2018cites this paper
• Hepatotoxicity issues associated with antineoplastic drug carmustine: a brief review

  2018cites this paper
• Brain Gliomas in the Elderly

  2017cites this paper
• Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma

  2017cites this paper
• Current Standards of Care in Glioblastoma Therapy

  2017influential citation
• Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution

  2017cites this paper
• Concurrent Chemotherapy of Malignant Glioma in Rats by Using Multidrug-Loaded Biodegradable Nanofibrous Membranes

  2016cites this paper
• Chapter 11 – Recurrent Glioblastoma

  2016cites this paper
• Anaplastic astrocytoma.

  2016cites this paper
• Therapeutic options in recurrent glioblastoma--An update.

  2016cites this paper
• Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes

  2016cites this paper
• Nitrosoureas in the Management of Malignant Gliomas

  2016cites this paper
• Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

  2016cites this paper
• Following the journey of seven patients with recurrent high grade glioma through hypo-fractionated salvage radiation therapy and beyond

  2016cites this paper
• Stereotactic Laser Interstitial Thermal Therapy for Recurrent High-Grade Gliomas.

  2016cites this paper
• Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma

  2015cites this paper
• Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review

  2015cites this paper
• Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas

  2015cites this paper
• PRACTICE GUIDELINE SERIES

  2015cites this paper
• Low pathogenic human enteroviruses as novel anti-cancer agents against malignant glioma

  2014cites this paper
• The role of neuropathology in the management of progressive glioblastoma

  2014cites this paper
• Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma

  2014cites this paper
• The role of cytotoxic chemotherapy in the management of progressive glioblastoma

  2014cites this paper
• Phase II Study of Bevacizumab Plus Irinotecan in Patients with Recurrent High-Grade Gliomas

  2013cites this paper
• Implanted Carmustine Wafers Followed by Concomitant Radiochemotherapy to Treat Newly Diagnosed Malignant Gliomas: Prospective, Observational, Multicenter Study on 92 Cases

  2013cites this paper
• Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model

  2013cites this paper
• Combined chemotherapy and immunotherapy against experimental malignant brain tumors

  2013cites this paper
• Update on the current management of glioblastoma

  2013cites this paper
• Bevacizumab and daily temozolomide for recurrent glioblastoma

  2012cites this paper
• Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas

  2012cites this paper
• Membrane raft disruption results in neuritic retraction prior to neuronal death in cortical neurons.

  2012cites this paper
• The Potential and Challenges of siRNA-Based Targeted Therapy for Treatment of Patients with Glioblastoma

  2012cites this paper
• Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis

  2012cites this paper
• Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.

  2012cites this paper
• Complications of chemotherapy in neuro-oncology.

  2012influential citation
• Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

  2012cites this paper
• Chemotherapy and target therapy in the management of adult high- grade gliomas.

  2012cites this paper
• Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.

  2012cites this paper
• Chapter 7 – Chemotherapy for Brain Tumors

  2012cites this paper
• Agents: Nitrosoureas, Cisplatin, Irinotecan

  2012cites this paper
• Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

  2012cites this paper
• Recent medical management of glioblastoma.

  2012cites this paper
• Avastin: more questions than answers. . .

  2012cites this paper
• Sensitivity to and functional effects of tricyclic agents on glioma: an immunohistochemical and in vitro study

  2011cites this paper
• Improving treatment outcomes in models of glioblastoma cancer

  2011influential citation
• Complications of Therapy

  2011cites this paper
• Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection.

  2011cites this paper
• Development of glioblastoma cell lines expressing red fluorescence for non-invasive live imaging of intracranial tumors.

  2011cites this paper
• Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma

  2011cites this paper
• Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

  2011cites this paper
• Evolution of care for patients with relapsed glioblastoma

  2011cites this paper
• Irinotecan and bevacizumab in recurrent glioblastoma multiforme

  2011cites this paper
• Therapeutic options for recurrent malignant glioma.

  2011cites this paper
• Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

  2011cites this paper
• Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging

  2011cites this paper
• Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.

  2010cites this paper
• Experimental approaches for the treatment of malignant gliomas.

  2010cites this paper
• Glioblastoma therapy: going beyond Hercules Columns

  2010cites this paper
• Irinotecan and BCNU-Impregnated Wafers Used in Combination, for the Treatment of Patients with Recurrent Glioblastoma Multiforme

  2010cites this paper
• Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends.

  2010cites this paper
• From Expert Review of Neurotherapeutics

  2010cites this paper
• From Expert Review of Anticancer Therapy

  2010cites this paper
• Chemotherapy for Glioblastoma: Past, Present, and Future

  2010cites this paper
• Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy

  2009cites this paper
• Treatment options for recurrent glioblastoma: pitfalls and future trends

  2009cites this paper
• Treatment of recurrent high-grade gliomas

  2009cites this paper
• A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

  2009cites this paper
• Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

  2009cites this paper
• Unmet needs in the treatment of glioblastoma

  2009cites this paper
• Extended-schedule dose-dense temozolomide in refractory gliomas

  2009cites this paper
• Improving the prognosis for patients with glioblastoma: the rationale for targeting Src

  2009cites this paper
• Nimustine (ACNU) Plus Teniposide (VM26) in Recurrent Glioblastoma

  2009cites this paper
• Experience with irinotecan for the treatment of malignant glioma.

  2009cites this paper
• When Temozolomide Alone Fails: Adding Procarbazine in Salvage Therapy of Glioma

  2008cites this paper
• Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma

  2008cites this paper
• Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

  2008cites this paper
• Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  2008cites this paper
• Topoisomerase I inhibitors for the treatment of brain tumors

  2008cites this paper
• Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

  2008cites this paper